Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Laudani, A. [1 ]
Savio, G. [1 ]
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Tartaglia, L. [1 ]
Manuguerra, G. [1 ]
Pepe, A. [1 ]
Alu, M. [1 ]
Usset, A. [1 ]
Agostara, B. [1 ]
机构：
[1] PO M Ascoli ARNAS Civico, Med Oncol Unit, Dept Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [2] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
  • [3] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [4] Capetabine plus irinotecan (CAPIRI) as first line treatment for patients with metastatic colorectal cancer(MCRC)
    Laudani, A.
    Alu, M.
    Leonardi, V
    Savio, G.
    Pepe, A.
    Palmisano, V
    Targaglia, L.
    Porretto, C.
    Manuguerra, G.
    Calabria, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : VII41 - VII41
  • [5] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
  • [6] Capecitabine (X) plus weekly irinotecan (CAPIRI) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from a phase II trial of the Brazilian Oncology Consordium
    Barrios, Carlos Henrique
    Viola, Fabiana
    Coura, Luciana
    Del Giglio, Auro
    Malhias, Clarissa
    ANNALS OF ONCOLOGY, 2004, 15 : 89 - 90
  • [7] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [8] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [9] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [10] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345